Clinical Trials Logo

Epilepsy, Generalized clinical trials

View clinical trials related to Epilepsy, Generalized.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03955432 Terminated - Focal Epilepsy Clinical Trials

Long-term Cardiac Monitoring in Epilepsy

LOOP
Start date: March 19, 2019
Phase: N/A
Study type: Interventional

The purpose of this research study to investigate, classify, and quantify chronic cardiac rhythm disorders in three groups of patients with epilepsy (intractable focal epilepsy, controlled focal epilepsy and symptomatic generalized epilepsy). Patients with epilepsy have a higher risk for cardiac complications than the general population. With this study, we aim to understand more about these potential complications in patients with epilepsy and assess if treatments for cardiac problems should be evaluated more carefully in patients with epilepsy.

NCT ID: NCT03831802 Terminated - Clinical trials for Epilepsy, Tonic-Clonic

Embrace and Quality of Life

EMBQL
Start date: October 10, 2018
Phase: N/A
Study type: Interventional

A prospective, open, randomized, pilot clinical trial which aims the assessment of quality of life (QOL) in epilepsy outpatients equipped with a wrist-worn biosensor that provides measures of electrodermal activity and accelerometry. These measures are used to automatically detect epileptic seizures that are transmitted to a mobile phone-based system for alerts and recording.

NCT ID: NCT00693017 Terminated - Epilepsy Clinical Trials

Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy

Start date: June 2008
Phase: Phase 3
Study type: Interventional

This study is intended to provide evidence that zonisamide is safe and effective in the treatment of myoclonic seizures. The total planned trial duration will be 6.5 months. After that, subjects who have completed the study will be eligible to enroll in an open-label extension study until zonisamide is marketed for this indication or further development in this indication stops. This extension study will be described in a separate protocol (E2090-E044-318).